Meridian Bioscience Inc Gets a Hold Rating from Canaccord Genuity

By Carrie Williams

Canaccord Genuity analyst Mark Massaro reiterated a Hold rating on Meridian Bioscience Inc (NASDAQ: VIVO) on October 10 and set a price target of $14. The company’s shares closed yesterday at $14.95.

According to TipRanks.com, Massaro is a 5-star analyst with an average return of 14.2% and a 56.0% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Orasure Technologies, and Idexx Laboratories.

Meridian Bioscience Inc has an analyst consensus of Moderate Sell, with a price target consensus of $12.67.

The company has a one-year high of $19.10 and a one-year low of $10.75. Currently, Meridian Bioscience Inc has an average volume of 205.2K.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VIVO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Meridian Bioscience, Inc. is a fully integrated life science company, which engages in the development, manufacture, sale, and distribution of diagnostic test kits, purified reagents, and related products and offers biopharmaceutical enabling technologies. It operates through the Diagnostics and Life Science segments.